

DAFTAR PUSTAKA

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA. Cancer J. Clin.*, vol. 68, no. 6, pp. 394–424, 2018.
- [2] World Health Organization, "Global Cancer Observatory : Cancer Today," *International Journal of Cancer*. [Online]. Available: <https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>
- [3] Kementerian Kesehatan, "Laporan Nasional Riskesdas 2018," *Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan*. pp. 1–674, 2018.
- [4] World Health Organization, "Indonesia - Global Cancer Observatory," *Int. J. Cancer*, p. 2, 2022.
- [5] American Cancer Society, "Facts & Figures 2020," *Atlanta Am. Cancer Soc.*, p. 76, 2020, [Online]. Available: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf>
- [6] R. A. Digambiro, A. ayu Armielie, and Y. B. Abadi, *Makanan dan Gaya Hidupmu Penyebab Kanker?*, 2nd ed. Bandung: Widina Media Utama, 2023. [Online]. Available: <https://repository.penerbitwidina.com/id/publications/565137/makanan-dan-gaya-hidupmu-penyebab-kanker>
- [7] R. Jan and G.-S. Chaundhry, "Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics," *Advanced Pharm. Bull.*, vol. 9, no. 2, pp. 205–218, 2019.
- [8] J. A. Perini, K. C. Rodrigues-Baptista, D. E. Machado, L. E. Nasciutti, and J. A. Perini, "Anticancer Potential, Molecular Mechanisms and Toxicity of *Euterpe oleracea* Extract (açai): A Systematic Review," *PLoS One*, vol. 13, no. 7, pp. 1–16, 2018.
- [9] I. Kapoor, J. Bodo, B. T. Hill, E. D. Hsi, and A. Almasan, "Targeting BCL-2 in B-cell Malignancies and Overcoming Therapeutic Resistance," *Cell Death Dis.*, vol. 11, no. 941, pp. 2–11, 2020.
- [10] B. El Dakkak *et al.*, "Unlocking the Therapeutic Potential of BCL-2

Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy,” *Biomol. Ther.*, vol. 32, no. 3, pp. 267–280, 2024.

- [11] F. Zahedipour, P. Kesharwani, and A. Sahebkar, “Mechanisms of Multidrug Resistance in Cancer Chemotherapy,” *Aptamers Eng. Nanocarriers Cancer Ther.*, vol. 21, no. 3233, pp. 51–83, 2022.
- [12] S. Khairani, S. A. Keban, and M. Afrianty, “Evaluation of Drug Side Effects Chemotherapy on Quality of Life (QOL) Breast Cancer Patients at Hospital X in Jakarta,” *J. Ilmu Kefarmasian Indones.*, vol. 17, no. 1, p. 9, 2019.
- [13] A. R. Khairullah *et al.*, “A Review of an Important Medicinal Plant: *Alpinia galanga* (L.) Willd,” *Syst. Rev. Pharm.*, vol. 11, no. 10, pp. 387–395, 2020.
- [14] M. Mujahid *et al.*, “A Review on Phytopharmacological Activity of *Alpinia Galanga*,” *Int. J. Pharm. Pharm. Sci.*, vol. 11, no. 3, pp. 6–11, 2019.
- [15] A. Chouni and S. Paul, “A Review on Phytochemical and Pharmacological Potential of *Alpinia galanga*,” *Pharmacogn. J.*, vol. 10, no. 1, pp. 9–15, 2018.
- [16] A. Suhendi, E. R. Wikantyasning, G. Setyadi, A. S. Wahyuni, and M. Da’i, “Acetoxy Chavicol Acetate (ACA) Concentration and Cytotoxic Activity of *Alpinia galanga* Extract on HeLa, MCF7 and T47D Cancer Cell Lines,” *Indones. J. Cancer Chemoprevention*, vol. 8, no. 2, pp. 79–82, 2017.
- [17] I. M. Aziz *et al.*, “Phytochemical analysis, antioxidant, anticancer, and antibacterial potential of *Alpinia galanga* (L.) rhizome,” *Heliyon*, vol. 10, no. 17, p. e37196, 2024.
- [18] N. D. Amalina, M. Suzery, B. Cahyono, and D. N. Bima, “Mengungkap Potensi Metabolit Sekunder Tanaman Herbal Indonesia untuk Menghentikan Metastasis Kanker Payudara: Pendekatan in-silico,” *Indones. J. Chem. Sci.*, vol. 9, no. 3, pp. 154–159, 2020, [Online]. Available: <http://journal.unnes.ac.id/sju/index.php/ijcs>
- [19] H. G. Gowtham *et al.*, “In Silico Computational Studies of Bioactive Secondary Metabolites from *Wedelia trilobata* against Anti-Apoptotic *B-Cell Lymphoma-2* (Bcl-2) Protein Associated with Cancer Cell Survival and Resistance,” *Molecules*, vol. 28, no. 4, pp. 1–16, 2023.
- [20] P. C. Agu *et al.*, “Molecular Docking As A Tool For The Discovery Of Molecular Targets Of Nutraceuticals In Diseases Management,” *Sci. Rep.*, vol. 13, no. 1, pp. 1–18, 2023.
- [21] R. Prasetiawati, “Studi Penambatan Molekul Senyawa Turunan Fenilpropanoid pada Tumbuhan Lengkuas (*Alpina galangal* (L.) Willd.) sebagai Obat Antikanker Otak,” *Parapemikir J. Ilm. Farm.*, vol. 11, no. 2, p. 189, 2022.

- [22] R. Muti'ah, A. Listiyana, B. B. Nafisa, and A. Suryadinata, "Kajian Efek Ekstrak Umbi Bawang Dayak (*Eleutherine palmifolia* (L.) Merr) sebagai Antikanker," *J. Islam. Pharm.*, vol. 5, no. 2, pp. 14–25, 2020.
- [23] E. Yanti, H. Harmawati, V. Irman, and R. I. Sari Dewi, "Peningkatan Kesiapan Pasien Kanker Menjalani Kemoterapi," *J. Abdimas Saintika*, vol. 3, no. 1, p. 85, 2021.
- [24] Z. Abbas and S. Rehman, "An Overview of Cancer Treatment Modalities Chapter," *Pract. Immunodermatology*, vol. 2, no. 6, pp. 279–296, 2016.
- [25] A. Saini, M. Kumar, S. Bhatt, V. Saini, and A. Malik, "Cancer Caouse and Treatments," *J. Int. Ilmu Farm.*, vol. 11, no. 7, pp. 3109–3122, 2020.
- [26] C. B. Blackadar, "Historical Review of the Causes of Cancer," *World J. Clin. Oncol.*, vol. 7, no. 1, pp. 54–86, 2016, doi: 10.5306/wjco.v7.i1.54.
- [27] P. Brennan and G. Davey-Smith, "Identifying Novel Causes of Cancers to Enhance Cancer Prevention: New Strategies Are Needed," *J. Natl. Cancer Inst.*, vol. 114, no. 3, pp. 353–360, 2022.
- [28] L. H. Nurani, Nurkhasanah, and L. M. Irham, *Kanker dan Karsinogenesis*, 1st ed., vol. 11, no. 1. Yogyakarta: UAD Press, 2023. [Online]. Available: http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_Sistem_Pembetungan_Terpusat_Strategi_Melestari
- [29] R. A. Digambiro and E. Parwanto, *Prinsip Terapi Kanker*, 1st ed., vol. 7, no. 2. Penerbit Underline, 2024.
- [30] N. Fitriatuzzakiyyah, R. K. Sinuraya, and I. M. Puspitasari, "Terapi Kanker dengan Radiasi: Konsep Dasar Radioterapi dan Perkembangannya di Indonesia," *J. Farm. Klin. Indones.*, vol. 6, no. 4, pp. 311–320, 2017.
- [31] H. Lawrenti, "Perkembangan Imunoterapi untuk Kanker," *J. Anal.*, vol. 45, no. 8, pp. 616–622, 2018.
- [32] İ. N. G. Atay, A. H. Gezer, and E. Kasap, "The Importance of Apoptosis in Cancer Development and Treatment," *Turkish J. Oncol.*, vol. 36, no. 3, pp. 381–388, 2021.
- [33] G. E. S. Chaudhry, A. Md Akim, Y. Y. Sung, and T. M. T. Sifzizul, "Cancer and Apoptosis: The Apoptotic Activity of Plant and Marine Natural Products and their Potential as Targeted Cancer Therapeutics," *Front. Pharmacol.*, vol. 13, no. August, pp. 1–24, 2022.
- [34] L. Sisinni *et al.*, "Endoplasmic Reticulum Stress and Unfolded Protein

Response in Breast Cancer: The Balance Between Apoptosis and Autophagy and its Role in Drug Resistance,” *Int. J. Mol. Sci.*, vol. 20, no. 4, 2019.

- [35] K. Matsuura, K. Canfield, W. Feng, and M. Kurokawa, *Metabolic Regulation of Apoptosis in Cancer*, vol. 327. Elsevier Inc., 2016.
- [36] G. Pistritto, D. Trisciuglio, C. Ceci, Alessia Garufi, and G. D’Orazi, “Apoptosis as Anticancer Mechanism: Function and Dysfunction of its Modulators and Targeted Therapeutic Strategies,” *Aging (Albany. NY)*, vol. 8, no. 4, pp. 603–619, 2016.
- [37] C. M. Pfeffer and A. T. K. Singh, “Apoptosis: A target for anticancer therapy,” *Int. J. Mol. Sci.*, vol. 19, no. 448, pp. 1–10, 2018.
- [38] S. Qian, Z. Wei, W. Yang, J. Huang, Y. Yang, and J. Wang, “The Role Of BCL-2 Family Proteins In Regulating Apoptosis And Cancer Therapy,” *Front. Oncol.*, vol. 12, no. 985363, pp. 1–16, 2022.
- [39] J. Ramos *et al.*, “Shedding light on the interaction of human anti-apoptotic Bcl-2 protein with ligands through biophysical and in silico studies,” *Int. J. Mol. Sci.*, vol. 20, no. 4, pp. 1–19, 2019, doi: 10.3390/ijms20040860.
- [40] S. Maji *et al.*, “BCL-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer,” *Adv. Cancer Res.*, vol. 137, no. 1, pp. 1–39, 2018.
- [41] S. Hafezi and M. Rahmani, “Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives,” *Cancers (Basel)*, vol. 13, no. 6, pp. 1–13, 2021.
- [42] L. M. Juárez-Salcedo, V. Desai, and S. Dalia, “Venetoclax: Evidence to date and clinical potential,” *Drugs Context*, vol. 8, no. 212574, pp. 1–13, 2019.
- [43] S. Cang, C. Iragavarapu, J. Savooji, Y. Song, and D. Liu, “ABT-199 (venetoclax) and BCL-2 Inhibitors in Clinical Development,” *J. Hematol. Oncol.*, vol. 8, no. 1, pp. 1–8, 2015.
- [44] F. Ong, K. Kim, and M. Y. Konopleva, “Venetoclax Resistance: Mechanistic Insights and Future Strategies,” *Cancer Drug Resist.*, vol. 5, no. 2, pp. 380–400, 2022.
- [45] A. K. Sharma *et al.*, “The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice,” *Front. Cell Dev. Biol.*, vol. 8, no. May, pp. 1–10, 2020.
- [46] S. Tao, J. Gu, Q. Wang, and L. Zheng, “Translational Control of Bcl-2 Promotes Apoptosis of Gastric Carcinoma Cells,” *BMC Cancer*, vol. 21, no. 12, pp. 1–10, 2021.

- [47] M. Klanova and P. Klener, "BCL-2 Proteins in Pathogenesis and Therapy of *B-Cell Non-Hodgkin Lymphomas*," *Cancers (Basel)*., vol. 12, no. 4, pp. 1–21, 2020.
- [48] A. Kawiak and A. Kostecka, "Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy," *Cancers (Basel)*., vol. 14, no. 279, pp. 1–28, 2022.
- [49] Y. Wei *et al.*, "Targeting Bcl-2 Proteins in Acute Myeloid Leukemia," *Front. Oncol.*, vol. 10, no. 5, pp. 1–11, 2020.
- [50] A. J. de M. Silva, J. E. de M. Gama, and S. A. de Oliveira, "The Role of Bcl-2 Family Proteins and Sorafenib Resistance in Hepatocellular Carcinoma," *Int. J. Cell Biol.*, vol. 2, no. 12, pp. 1–12, 2024.
- [51] P. L. Sun, H. Sasano, and H. Gao, "BCL-2 Family in Non-Small Cell Lung Cancer: its Prognostic and Therapeutic Implications," *Pathol. Int.*, vol. 67, no. 3, pp. 121–130, 2017, doi: 10.1111/pin.12507.
- [52] J. Xu, X. Dong, D. C. S. Huang, P. Xu, Q. Zhao, and B. Chen, "Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers," *Cancers (Basel)*., vol. 15, no. 20, pp. 1–24, 2023.
- [53] Y. Xu and H. Ye, "Progress in Understanding the Mechanisms of Resistance to BCL-2 Inhibitors," *Exp. Hematol. Oncol.*, vol. 11, no. 1, pp. 1–11, 2022.
- [54] I. A. K. Pramushinta and P. S. Ajiningrum, "Uji Aktivitas Sel Kanker dengan menggunakan senyawa Flavonoid dari Lengkuas (*Alpinia Galanga*)," *STIGMA J. Mat. dan Ilmu Pengetah. Alam Unipa*, vol. 10, no. 02, pp. 88–92, 2017.
- [55] P. N. Ravindran, *The Encyclopedia of Herbs and Spices*, vol. 2, no. 7/8. Boston: CABI Digital Library Terms & Conditions, 2017.
- [56] M. P. K. Pradani, M. P. Rahayu, R. Harjanti, and P. P. Haresmita, "Profil Ekstrak Rimpang Lengkuas (*Alpinia galanga* (L.) Willd.) dari Lokasi Tanam dengan perbedaan Letak Ketinggian Geografis," *Pharm. J. Farm. Indones.*, vol. 21, no. 01, 2024.
- [57] M. Alqamari, D. M. Tarigan, and Alridiwersah, *Budidaya Tanaman Obat & Rempah*. 2017.
- [58] Q. A. P. Priyono *et al.*, "Ethnomedical Potentials, Phytochemicals and Medicinal Profile of *Alpinia galanga* L.: A Comprehensive Review," *BIO Integr.*, vol. 5, no. 1, pp. 1–9, 2024.
- [59] Y. Q. Zhou *et al.*, *A Review of the Botany, Phytochemical, and Pharmacological Properties of Galangal*, vol. 7. Elsevier Inc., 2018. doi:

10.1016/C2016-0-00380-7.

- [60] M. O. Aljobair, "Chemical Composition, Antimicrobial Properties and Antioxidant Activity of *Galangal Rhizome*," *Food Sci. Technol.*, vol. 42, pp. 1–8, 2022.
- [61] C. Zhou, C. Li, S. Siva, H. Cui, and L. Lin, "Chemical Composition, Antibacterial Activity and Study of the Interaction Mechanisms of the Main Compounds Present in the *Alpinia galanga* Rhizomes Essential Oil," *Ind. Crops Prod.*, vol. 165, no. 1, p. 113441, 2021.
- [62] R. D. S. Toba, H. Hafid, and M. A. Pagala, "Kualitas Organoleptik Daging Sapi Yang Diberi Pasta Lengkuas (*Alpinia galanga* L.) Dengan Lama Simpan Yang Berbeda," *J. Ilmu dan Teknol. Peternak. Trop.*, vol. 5, no. 1, p. 26, 2018.
- [63] S. Sahoo *et al.*, "Molecular And Phytochemical Stability of Long Term Micropropagated Greater Galanga (*Alpinia galanga*) Revealed Suitable for Industrial Applications," *Ind. Crops Prod.*, vol. 148, no. February, p. 112274, 2020.
- [64] M. A. Rahim, X. Zhang, and N. Busatto, "Editorial: Phenylpropanoid Biosynthesis in Plants," *Front. Plant Sci.*, vol. 14, pp. 1–3, 2023.
- [65] Neelam, A. Khatkar, and K. K. Sharma, "Phenylpropanoids and its Derivatives: Biological Activities and its Role in Food, Pharmaceutical and Cosmetic Industries," *Crit. Rev. Food Sci. Nutr.*, vol. 60, no. 16, pp. 2655–2675, 2020.
- [66] M. Ramarosan, C. Koutouan, J. Helesbeux, L. Hamama, E. Geoffriau, and M. Briard, "Role of Phenylpropanoids and Flavonoids in Plant Resistance to Pests and Diseases," *Molecules*, vol. 27, no. 8371, pp. 1–24, 2022.
- [67] M. Da'i, K. A. Meilinasary, A. Suhendi, and S. Haryanti, "Selectivity Index of *Alpinia galanga* Extract and 1'-Acetoxychavicol Acetate on Cancer Cell Lines," *Indones. J. Cancer Chemoprevention*, vol. 10, no. 2, p. 95, 2019.
- [68] A. W. Nugroho and A. Fauzi, "Studi Docking Molekuler Senyawa Turunan *Acetoxychavicol Acetat* (ACA) pada Protein Target ER-A, ER-B, dan HER-2 sebagai Agen Sitotoksik," *J. Farmasetis*, vol. 13, no. 3, pp. 111–122, 2024.
- [69] A. Kojima-Yuasa and I. Matsui-Yuasa, "Pharmacological Effects of 1'-*Acetoxychavicol Acetate*, a Major Constituent in the Rhizomes of *Alpinia galanga* and *Alpinia conchigera*," *J. Med. Food*, vol. 23, no. 5, pp. 465–475, 2020.
- [70] N. Pradubyat *et al.*, "1'-*Acetoxychavicol Acetate* from *Alpinia galanga* Represses Proliferation and Invasion, and Induces Apoptosis via HER2-

- signaling in Endocrine-Resistant Breast Cancer Cells,” *Planta Med.*, vol. 88, no. 2, pp. 163–178, 2022.
- [71] F. Wulandari, A. Fauzi, M. Da’i, M. Mirzaei, Maryati, and K. Harismah, “Screening and identification of potential target of *1'-acetoxychavicol acetate* (ACA) in acquired lapatinib-resistant breast cancer,” *Heliyon*, vol. 10, no. 23, p. e40769, 2024.
- [72] J. de Ryuck, G. Brysbaert, R. Blossey, and M. F. Lensink, “Molecular Docking as a Popular Tool in Drug Design, an in Silico Travel,” *Adv. Appl. Bioinforma. Chem.*, vol. 9, no. 1, pp. 1–11, 2016.
- [73] L. Pinzi and G. Rastelli, “Molecular Docking: Shifting Paradigms in Drug Discovery,” *Int. J. Mol. Sci.*, vol. 20, no. 18, pp. 1–23, 2019.
- [74] S. Ahmad, S. Singh, M. R. Srivastava, S. Shukla, S. Rai, and A. S. Shamsi, “Molecular Docking Simplified: Literature Review,” *Adv. Medical, Dent. Heal. Sci.*, vol. 4, no. 4, pp. 37–44, 2022, [Online]. Available: www.amdhs.org
- [75] P. J. Pratama, N. Kurniawati, and S. Erikania, “Uji In Silico Senyawa Daun Belimbing Wuluh (*Averrhoa bilimbi* L.) Sebagai Antikanker Kolorektal Serta Prediksi Profil Farmakokinetik Dan Toksisitas,” in *Prosiding Seminar Informasi Kesehatan Nasional (SIKESNAS)*, 2023, pp. 25–40. [Online]. Available: <https://pubchem.ncbi.nlm.nih.gov/>
- [76] A. Hakiki, A. Andika, and R. Rahmawati, “Studi Molecular Docking dan Prediksi ADMET Senyawa Turunan Kurkumin Sebagai Inhibitor Kasein Kinase 2- α ,” *Lambung Farm. J. Ilmu Kefarmasian*, vol. 5, no. 2, pp. 195–212, 2024.
- [77] P. K. Kalontong, M. Safithri, and K. Tarman, “Penambatan Molekul Senyawa Aktif *Spirulina platensis* sebagai Inhibitor TMPRSS2 untuk Mencegah Infeksi SARS-COV-2,” *J. Pengolah. Has. Perikan. Indones.*, vol. 25, no. 2, pp. 253–267, 2022.
- [78] A. N. Fransiska *et al.*, “Literature Review: Molecular Docking Aktivitas Senyawa Antioksidan Alami pada Beberapa Tanaman di Indonesia,” *J. Farmasetis*, vol. 12, no. 1, pp. 55–60, 2023.
- [79] M. T. Muhammed and E. Aki-Yalcin, “Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery,” *Lett. Drug Des. Discov.*, vol. 21, no. 3, pp. 480–495, 2022.
- [80] Í. F. Protti, D. R. Rodrigues, S. K. Fonseca, R. J. Alves, R. B. de Oliveira, and V. G. Maltarollo, “Do Drug-likeness Rules Apply to Oral Prodrugs?,” *ChemMedChem*, vol. 16, no. 9, pp. 1446–1456, 2021.

- [81] L. Z. Benet, C. M. Hosey, O. Ursu, and T. I. Oprea, "BDDCS, the Rule of 5 and drugability," *Adv. Drug Deliv. Rev.*, vol. 101, pp. 89–98, 2016.
- [82] V. Ivanović, M. Rančić, B. Arsić, and A. Pavlović, "Lipinski's Rule of Five, Famous Extensions and Famous Exceptions," *Chem. Naissensis*, vol. 3, no. 1, pp. 171–177, 2020.
- [83] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings," *Adv. Drug Deliv. Rev.*, vol. 64, no. 2, pp. 4–17, 2012.
- [84] M. Shofi, "Analysis of a-spinasterol Compounds in Trembesi Seeds (*Samanea saman* (jacq.) Merr) Against Inhibition of 3C-like Protease SARS-CoV-2 Through In Silico Test," *J. Sint. Penelit. Sains, Terap. dan Anal.*, vol. 2, no. 2, pp. 74–88, 2022.
- [85] A. Daina, O. Michielin, and V. Zoete, "Swissadme: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules," *Sci. Rep.*, vol. 7, no. January, pp. 1–13, 2017.
- [86] R. Poduri, *Drug Discovery and Development: From Targets and Molecules to Medicines*, no. 1. 2021.
- [87] H. Yang, L. Sun, W. Li, G. Liu, and Y. Tang, "In Silico Prediction of Chemical Toxicity for Drug Design Using Machine Learning Methods and Structural Alerts," *Front. Chem.*, vol. 6, no. 30, pp. 1–12, 2018.
- [88] D. E. V. Pires, T. L. Blundell, and D. B. Ascher, "pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures," *J. Med. Chem.*, vol. 58, no. 9, pp. 4066–4072, 2015.
- [89] Salman, Firawati, D. Setiawan, Nuradi, Muzayyidah, and U. Samsidar, *Farmakokinetika*. Purbalingga: Eureka Media Aksara, 2024.
- [90] M. Z. Maulida, D. Ummahati, and L. N. Muna, "Analisis Sifat Fisikokimia, Farmakokinetik, Dan Toksisitas Senyawa Aktif Dalam Jahe Merah (*Zingiber Officinale* Var *Rubrum Rhizoma*)," *J. Pharm. Care Sci.*, vol. 4, no. 1, pp. 90–98, 2023.
- [91] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik san Toksikologi pada *Pericarpium Pala* (*Myristica Fragrans*) secara Artificial Intelligence," *Chem. Prog.*, vol. 14, no. 2, p. 81, 2021.
- [92] F. A. Febri, T. Chilfi, A. F. Salamah, and A. Wilipangga, "Analisis Farmakokinetik dan Toksisitas pada Kandungan Fenolik Ekstrak Daun Salam (*Syzygium polyanthum*) menggunakan In Silico pkCMS Dan Protok

- II,” *J. Bina Cipta Husada*, vol. 19, no. 1, pp. 108–117, 2023.
- [93] F. Fadhilah Faza and D. Kesuma, “Prediksi ADMET dan Molecular Docking Metabolit Sekunder *Centella asiatica* sebagai Obat Antikanker Payudara,” *Pharmacoscript*, vol. 7, no. 1, pp. 1–12, 2024.
- [94] B. T. Purwanto and H. Poerwono, “Uji In Silico Aktivitas Analgesik dan Toksisitas Molekul Turunan *N*-Benzoil-*N*’-4-Metoksifeniltiourea sebagai Kandidat Obat Analgesik,” *J. Wiyata Penelit. Sains Kesehat.*, vol. 11, no. 2, pp. 165–173, 2024.
- [95] A. Tilaqza, M. Herbani, and Z. Aqilah, “Studi Docking Molekuler Penghambatan Reseptor Neprilysin Bunga Lawang (*Illicium verum*) sebagai Anti Hipertensi dan Prediksi Profil Farmakokinetikanya,” *J. Ilm. Biosaintropis*, vol. 9, no. 1, pp. 52–62, 2023.
- [96] Herdini and I. R. Setyawati, “Studi In Silico: Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*) terhadap Penghambatan Reseptor *Human Chitotriosidase-1* (hCHIT1) sebagai Antiasma,” *Sainstech J. Penelit. Dan Pengkaj. Sains Dan Teknol.*, vol. 33, no. 2, pp. 91–107, 2023.
- [97] O. Nursanti, A. Aziz, and G. Hadisoebroto, “Prediksi Toksisitas dan Farmakokinetika untuk mendapatkan Kandidat Obat Analgesik,” *J. Noncommunicable Dis.*, vol. 3, no. 1, pp. 34–46, 2023.
- [98] R. Manjari, “Understanding Drug-Receptor Interactions: Unlocking the Secrets of Pharmaceutical Action,” *J. Med. Org. Chem.*, vol. 6, no. 4, pp. 100–103, 2023.
- [99] Siswandono, *Kimia Medisinal 1 Edisi 2*, 2nd ed. Surabaya: Airlanngga University Press, 2016. [Online]. Available: https://books.google.co.id/books/about/Kimia_Medisinal_1_Edisi_2.html?id=UKbJDwAAQBAJ&redir_esc=y
- [100] M. Nuraini and Ruswanto, “Studi In Silico Senyawa Galangin Lengkuas (*Alpinia galanga*) Sebagai Antikanker Terhadap Kanker Payudara,” in *Prosiding Seminar Nasional dan Penelitian Kesehatan*, 2021, pp. 178–191.
- [101] D. Dwirosalia, I. Yustisia, A. Arsyad, R. Natsir, M. H. Cangara, and I. Patellongi, “Studi In Silico Potensi Anti Kanker Senyawa Turunan Kumarin terhadap Protein BCL-2,” *Maj. Farm. dan Farmakol.*, vol. 25, no. 2, pp. 80–83, 2021.
- [102] P. RSCB, “Structure of Human BCL-2 in Complex with Analogue of ABT-737.” [Online]. Available: <https://www.rcsb.org/structure/6QGG>
- [103] G. Chen, A. J. Seukep, and M. Guo, “Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs,” *Mar. Drugs*, vol.

18, no. 11, 2020.

- [104] A. U. Hanif, P. A. Lukis, and A. Fadlan, "Pengaruh Minimisasi Energi MMFF94 dengan MarvinSketch dan Open Babel PyRx pada Penambatan Molekular Turunan Oksindola Tersubstitusi," *ALCHEMY J. Chem.*, vol. 8, no. 2, pp. 33–40, 2020.
- [105] T. Lewis-Atwell, P. A. Townsend, and M. N. Grayson, "Comparing the Performances of Force Fields in Conformational Searching of Hydrogen-Bond-Donating Catalysts," *J. Org. Chem.*, vol. 87, no. 9, pp. 5703–5712, 2022.
- [106] Á. Jász, Á. Rák, and G. Cserey, "Energy Calculation of MMFF94 Force Field on GPU," in *European Conference on Circuit Theory and Design (ECCTD)*, 2017, pp. 1–4.
- [107] M. D. Widyastuti, N. K. M. Noviyanti, I. K. N. S. Sanjaya, and N. M. P. Susanti, "Aktivitas Antihiperpigmentasi Likopen secara in Silico," *J. Kim.*, vol. 14, no. 2, p. 107, 2020.
- [108] N. M. P. Susanti, N. P. L. Laksmiani, N. K. M. Noviyanti, K. M. Arianti, and I. K. Duantara, "Molecular Docking *Terpinen-4-Ol* sebagai Antiinflamasi pada Aterosklerosis secara in Silico," *J. Kim.*, vol. 13, no. 2, pp. 221–228, 2019.
- [109] F. Z. Muttaqin, M. F. Pratama, and F. Kurniawan, "Molecular Docking and Molecular Dynamic Studies of Stilbene Derivative Compounds *As Sirtuin-3* (SIRT3) Histone Deacetylase Inhibitor on Melanoma Skin Cancer and Their Toxicities Prediction," *J. Pharmacopolium*, vol. 2, no. 2, pp. 112–121, 2019.
- [110] M. F. Hariz, "Uji Sitotoksik, Toksisitas dan Prediksi Sifat Fisikokimia Senyawa *Isoliquiritigenin* dan *Oxyresveratrol* terhadap Reseptor *B-Cell Lymphoma 2* (4AQ3) dan *Endothelial Growth Factor Receptor-2* (2RL5) sebagai Terapi Kanker Serviks secara In Silico," Universitas Islam Negeri Maulana Malik Ibrahim Malang, 2019.
- [111] A. Pangastuti, M. Amin, and S. E. Indriwati, "Mengungkap Potensi Antiaging Alami Secara In Silico," in *Prosiding Seminar Nasional II*, 2016, pp. 668–674. [Online]. Available: <https://pubchem.ncbi.nlm.nih.gov>
- [112] S. Amin, R. Aryanti, and A. Y. Aprilia, "Studi In Silico Senyawa yang Terkandung dalam Kulit Buah Manggis (*Garcinia mangostana* L.) Sebagai Antikanker Payudara," *Pros. Semin. Nas. Disem. Penelit.*, vol. 3, no. September, pp. 2964–6154, 2023, [Online]. Available: <https://zlab.umassmei>
- [113] E. Di Cera, "Mechanisms of Ligand Binding," *Biophys. Rev.*, vol. 1, no. 1, pp. 1–27, 2020.

- [114] D. Nelsari, “Studi in Silico Daun Dewandaru (*Eugenia uniflora* L.) sebagai Anti-Tirosinase,” Institut Sains dan Teknologi Nasional Jakarta, 2023.
- [115] I. A. P. Neshich *et al.*, “Computational Biology Tools for Identifying Specific Ligand Binding Residues for Novel Agrochemical and Drug Design Computational Biology Tools for Identifying Specific Ligand Binding Residues for Novel Agrochemical and Drug Design,” *Curr. Protein Pept. Sci.*, vol. 16, no. 2, pp. 701–717, 2015.
- [116] P. P. Venugopal, B. K. Das, E. Soorya, and D. Chakraborty, “Effect of Hydrophobic and Hydrogen Bonding Interactions on the Potency of β -alanine Analogs of *G-protein Coupled Glucagon Receptor Inhibitors*,” *Proteins Wiley*, vol. 12, no. 2, pp. 1–18, 2019.
- [117] S. Nurjannah, “Studi In Silico Senyawa *Peronemin Cl* dan Turunannya dari Daun Sungkai (*Peronema canescens* Jack) sebagai Anti-Inflamasi,” Universitas Jambi, 2024.
- [118] H. Lailiyyah and L. Lisdiana, “Uji Aktivitas Antibakteri Senyawa Aktif Temu Kunci (*Boesenbergia rotunda*) Terhadap *Mycobacterium tuberculosis* Secara In Silivo,” *LenteraBio Berk. Ilm. Biol.*, vol. 12, no. 2, pp. 132–149, 2023.
- [119] G. D. Ahadi and N. N. L. E. Zain, “The Simulation Study of Normality Test Using *Kolmogorov-Smirnov, Anderson-Darling*, and *Shapiro-Wilk*,” *Eig. Math. J.*, vol. 6, no. 1, pp. 11–19, 2023.
- [120] Z. Zulkipli, Z. Zulfachmi, and A. Rahmad, “Alasan Peneliti Menggunakan Analisis Statistik *Wilcoxon* (Non Parametrik),” in *Prosiding Seminar Nasional Ilmu Sosial & Teknologi (SNISTEK)*, 2024, pp. 119–125.
- [121] R. Sianturi, “Uji Normalitas sebagai Syarat Pengujian Hipotesis,” *J. Pembelajaran Dan Mat. Sigma*, vol. 10, no. 2, pp. 133–138, 2024.
- [122] Y. A. Ermandy, “Prediksi Toksisitas Aktivitas Antivirus Senyawa Golongan Monoterpen pada *Mentha piperita* L. terhadap Reseptor *Main Protease* (6M2N) sebagai Terapi *SARS-CoV-2* secara In Silico,” Universitas Islam Negeri Maulana Malik Ibrahim Malang, 2021.
- [123] R. A. Permata, Syaidatussalihah, and Abdurahim, “Analisis Data Penelitian Kesehatan: Perbandingan Hasil antara SmartPLS, R dan IBM SPSS untuk Jumlah Sampel Kecil,” *JSN J. Sains Nat.*, vol. 1, no. 1, pp. 17–22, 2023.
- [124] Adriani, “Prediksi Senyawa Bioaktif dari Tanaman Sanrego (*Lunasia amara Blanco*) Sebagai Inhibitor Enzim *Siklooksigenase-2* (COX-2) Melalui Pendekatan Molecular Docking,” *J. Ilm. Pena*, vol. 1, no. 1, pp. 6–11, 2018.
- [125] M. Natural *et al.*, “Studi In Silico Prediksi Sifat Fisikokimia dan Toksisitas

Senyawa *Tectoquinone* Sebagai α -Glukosidase Inhibitor,” *Makassar Nat. Prod. J.*, vol. 2, no. 3, pp. 215–221, 2024.

- [126] W. A. Kartika, A. A. Silalahi, Athaillah, R. Rambe, and F. P. Fattara, “Molecular Docking Meniran (*Phyllanthus niruri* L.) terhadap Penghambatan Enzim *Tyrosine Kinase* sebagai Antikanker,” *Indones. J. Pharm. Clin. Res.*, vol. 07, no. 02, pp. 14–24, 2024.
- [127] K. M. Al Azzam, “SwissADME and pkCSM Webservers Predictors: an integrated Online Platform for Accurate and Comprehensive Predictions for In Silico ADME/T Properties of Artemisinin and its Derivatives,” *Kompleks. Ispolz. Miner. Syra*, vol. 325, no. 2, pp. 14–21, 2023.
- [128] K. D. Anandhy, “Studi Komputasi Prediksi Profil Farmakokinetik, Toksisitas dan Molecular Docking Kandungan Senyawa Daun Insulin (*Tithonia diversifolia* Hemsl A. Gray) pada berbagai Target Protein Terapi Nefropati Diabetik,” Universitas Brawijaya Malang, 2021.
- [129] A. D. P. Komarudin, M. F. G. Purnama, M. F. G. Purnama, A. Y. Sari, E. N. M. Rizka Sahila, and A. Izzati, “Studi in Silico Senyawa Tanaman *Nerium oleander* terhadap *STAT-3* pada Kanker Payudara,” *J. Farm. Udayana*, vol. 10, no. 2, pp. 149–155, 2021.
- [130] M. S. Latif, T. Rusdiana, and D. Gozali, “Pengaruh *P-Glycoprotein* (P-GP) terhadap Bioavailabilitas Atorvastatin,” *Farmaka*, vol. 15, no. 3, pp. 1–6, 2018.
- [131] D. Š. Mustapć, Ž. Debeljak, Ž. Maleš, and M. Bojć, “The inhibitory effect of flavonoid aglycones on the metabolic activity of CYP3A4 enzyme,” *Molecules*, vol. 23, no. 10, pp. 1–12, 2018.
- [132] A. Tilaqza and M. Herbani, “Studi In silico Potensi Anti Hipertensi dan Prediksi Profil Farmakokinetika Daun Jati Belanda (*Guazuma ulmifolia* Lamk),” *J. Kesehat. Islam Islam. Heal. J.*, vol. 10, no. 2, p. 45, 2021.
- [133] L. S. K. Konda, S. Keerthi Praba, and R. Kristam, “hERG Liability Classification Models using Machine Learning Techniques,” *Comput. Toxicol.*, vol. 12, no. 2, pp. 1–9, 2019.